XTX Topco Ltd Cuts Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

XTX Topco Ltd trimmed its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 87.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,782 shares of the company's stock after selling 223,267 shares during the period. XTX Topco Ltd's holdings in Xeris Biopharma were worth $72,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Simplicity Wealth LLC acquired a new stake in shares of Xeris Biopharma during the 2nd quarter worth about $27,000. Bayesian Capital Management LP acquired a new position in Xeris Biopharma in the 1st quarter valued at $37,000. Allspring Global Investments Holdings LLC raised its holdings in Xeris Biopharma by 4,512.5% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 16,282 shares of the company's stock valued at $37,000 after acquiring an additional 15,929 shares during the last quarter. Quarry LP purchased a new position in shares of Xeris Biopharma during the 4th quarter worth $47,000. Finally, Eagle Asset Management Inc. acquired a new stake in shares of Xeris Biopharma during the fourth quarter worth $48,000. Hedge funds and other institutional investors own 42.75% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a "buy" rating and set a $6.00 target price on shares of Xeris Biopharma in a research report on Thursday, August 15th.

Xeris Biopharma Price Performance

XERS stock traded up $0.12 on Wednesday, hitting $2.91. 1,231,773 shares of the company were exchanged, compared to its average volume of 1,750,247. The stock has a market capitalization of $431.42 million, a price-to-earnings ratio of -6.19 and a beta of 2.76. Xeris Biopharma Holdings, Inc. has a twelve month low of $1.46 and a twelve month high of $3.26. The business's fifty day moving average is $2.67 and its two-hundred day moving average is $2.29.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.01. Xeris Biopharma had a negative return on equity of 16,662.63% and a negative net margin of 32.83%. The business had revenue of $48.07 million during the quarter, compared to the consensus estimate of $46.80 million. During the same period in the prior year, the firm posted ($0.14) EPS. Equities research analysts expect that Xeris Biopharma Holdings, Inc. will post -0.4 earnings per share for the current year.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.